Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2032018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study.
Jpn J Clin Oncol
January 2025
Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishishimbashi, Minato-ku, Tokyo 105-8461, Japan.
Background: The JAVELIN Bladder 100 trial demonstrated improved overall survival (OS) with maintenance avelumab in patients with locally advanced or metastatic urothelial carcinoma UC (la/mUC) who achieved disease control following first-line platinum-based chemotherapy (1 L-PBC). However, real-world data on eligibility, utilization, and outcomes of maintenance avelumab therapy remain limited.
Methods: This retrospective study included patients with la/mUC who received 1 L-PBC.
Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study.
Future Oncol
January 2025
hUniversity of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-line Platinum-based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05).
Cancer Res Treat
December 2024
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
View Article and Find Full Text PDFCase report: Two cases of leptomeningeal metastases in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.
Front Oncol
November 2024
Department of Medicine, Medical Oncology Division, British Columbia (BC) Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada.
Article Synopsis
- Leptomeningeal carcinomatosis is a rare metastatic pattern in genitourinary cancer, found in less than 0.1% of cases, and can occur even after initial treatments with enfortumab vedotin (EV).
- Two cases of metastatic urothelial cancer are presented: both patients initially showed positive responses to EV but later developed severe neurologic symptoms due to leptomeningeal metastases confirmed through imaging and cytology.
- The cases highlight an unusual progression pattern among patients treated with EV, suggesting the need for further investigation into this type of cancer spread.
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab.
Clin Genitourin Cancer
November 2024
Barts Cancer Institute, Queen Mary University of London, London, UK.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!